articleTop 1% cited

Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

Ophthalmology · 2011 · Vol. 118(10) · pp. 2041–2049

Peter A. Campochiaro✉(Johns Hopkins University)David M. Brown(Retina Consultants of Houston)Carl C. Awh(Tennessee Retina)Sang-Ho Lee(Retina Research Institute of Texas)Sarah GrayNamrata SarojWendy Yee MurahashiRoman G. Rubio

View via DOI Publisher page

Retinal Diseases and Treatments Retinal and Optic Conditions Ocular Diseases and Behçet’s SyndromeMedicineRanibizumabCentral retinal vein occlusionMacular edemaOphthalmologyVisual acuityRandomized controlled trialConfidence intervalSurgeryBevacizumab

MeSH terms

RanibizumabAdolescentDouble-Blind MethodFluorescein AngiographyHumansMacular EdemaProspective StudiesRetinal Vein OcclusionVisual AcuityTreatment OutcomeTomography, Optical CoherenceYoung AdultInjections, IntraocularAntibodies, Monoclonal, Humanized

Citations

700

FWCI

46.41

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Effect of intravitreal Bevacizumab on macular edema secondary to retinal vascular occlusion